Common Interest Doctrine and Attorney-Client Privilege Protect Distributor’s Email Communication with Defendant

Feb 3, 2020

Reading Time : 1 min

Plaintiff, Beijing Choice Electronic Technology Co., Ltd. (“Choice”) sued Contec Medical Systems USA, Inc. and Contec Medical Systems Co., Ltd. (collectively, “Contec”) for infringing Choice’s patents related to fingertip pulse oximeters. After the complaint had been filed, an attorney for Choice sent cease-and-desist letters to six Contec distributors, including Veridian Healthcare LLC (“Veridian”). Veridian, in turn, sought advice via email from Contec regarding how best to respond to the cease-and-desist letter. Choice subpoenaed Veridian documents, including its emails and later moved to compel production after Veridian withheld the material on the basis of attorney-client privilege.

The court held that privilege attached to a single email—a filtered summary of an attorney’s opinions regarding the litigation that was primarily legal in nature. The court also found the document implicated the common interest doctrine. Veridian purchased oximeters from Contec that were at the center of the litigation, and after receiving the cease-and-desist letter, Veridian reasonably understood it might face its own lawsuit for selling the allegedly infringing products. The document thus concerned coordination between Veridian and Contec, both of which had an actual legal interest in avoiding liability. Because the privileged status of communications falling within the common interest doctrine cannot be waived without the consent of all parties, the court found the document properly withheld as privileged.

The court held that the remaining documents were not protected by the attorney-client privilege or work product immunity. The court determined the documents did not reveal the substance of any client confidence or opinions of Contec’s counsel. Instead, the documents involved business discussions. As such, the court ordered Veridian to produce them.

Beijing Choice Elec. Tech. Co. v. Contec Med. Sys. USA, Inc., No. 1:18-CV-825, D.I. 182 (N.D. Ill. Jan. 14, 2020)

Share This Insight

Previous Entries

IP Newsflash

November 17,2025

The district of Delaware recently denied a defendant’s partial motion to dismiss pre-suit willful infringement from the litigation, finding instead that the allegations taken as a whole were sufficient to support pre-suit willfulness at the pleading stage. Specifically, the court found that the allegations as to the defendant’s involvement in a related foreign opposition proceeding and participation in the relevant industry were accompanied by detailed factual support that sufficiently pleaded willful infringement for the pre-suit period.

...

Read More

IP Newsflash

November 14, 2025

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

...

Read More

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.